Telix Pharmaceuticals (TLX) Competitors $9.42 -0.09 (-0.95%) Closing price 04:00 PM EasternExtended Trading$9.44 +0.03 (+0.27%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLX vs. RDY, ASND, VTRS, QGEN, BBIO, ROIV, ELAN, VRNA, MRNA, and RVMDShould you be buying Telix Pharmaceuticals stock or one of its competitors? The main competitors of Telix Pharmaceuticals include Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Moderna (MRNA), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Telix Pharmaceuticals vs. Its Competitors Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris QIAGEN BridgeBio Pharma Roivant Sciences Elanco Animal Health Verona Pharma PLC American Depositary Share Moderna Revolution Medicines Dr. Reddy's Laboratories (NYSE:RDY) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation. Is RDY or TLX more profitable? Dr. Reddy's Laboratories has a net margin of 16.99% compared to Telix Pharmaceuticals' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 17.25% beat Telix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories16.99% 17.25% 11.63% Telix Pharmaceuticals N/A N/A N/A Do analysts rate RDY or TLX? Dr. Reddy's Laboratories presently has a consensus target price of $16.95, indicating a potential upside of 15.07%. Telix Pharmaceuticals has a consensus target price of $21.33, indicating a potential upside of 126.47%. Given Telix Pharmaceuticals' higher probable upside, analysts plainly believe Telix Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80Telix Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media refer more to RDY or TLX? In the previous week, Telix Pharmaceuticals had 9 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 14 mentions for Telix Pharmaceuticals and 5 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.14 beat Telix Pharmaceuticals' score of 0.28 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in RDY or TLX? 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has preferable valuation and earnings, RDY or TLX? Dr. Reddy's Laboratories has higher revenue and earnings than Telix Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$3.81B3.23$663M$0.6622.32Telix Pharmaceuticals$516.72M6.17$32.93MN/AN/A SummaryDr. Reddy's Laboratories beats Telix Pharmaceuticals on 9 of the 13 factors compared between the two stocks. Get Telix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TLX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLX vs. The Competition Export to ExcelMetricTelix PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.19B$3.08B$5.69B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E RatioN/A21.3075.8626.51Price / Sales6.17379.80489.92165.32Price / Cash80.6544.4425.8129.89Price / Book8.419.6112.846.32Net Income$32.93M-$53.28M$3.28B$270.51M7 Day Performance1.40%0.30%0.20%2.15%1 Month Performance-18.37%4.57%4.59%6.35%1 Year PerformanceN/A9.23%68.31%25.48% Telix Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLXTelix Pharmaceuticals3.6411 of 5 stars$9.42-0.9%$21.33+126.5%N/A$3.19B$516.72M0.00N/ARDYDr. Reddy's Laboratories2.426 of 5 stars$14.64-0.2%$16.95+15.8%-9.0%$12.24B$3.81B22.1727,811Positive NewsASNDAscendis Pharma A/S2.9554 of 5 stars$194.62-0.5%$244.36+25.6%+63.2%$11.97B$393.54M-37.721,017Positive NewsVTRSViatris1.5918 of 5 stars$9.60-3.6%$10.40+8.3%-17.7%$11.61B$14.74B-3.3132,000High Trading VolumeQGENQIAGEN4.4124 of 5 stars$45.39+0.2%$49.69+9.5%+0.7%$10.07B$1.98B26.825,765BBIOBridgeBio Pharma4.4324 of 5 stars$51.47+0.5%$63.94+24.2%+96.6%$9.79B$221.90M-12.58400Analyst ForecastROIVRoivant Sciences2.9607 of 5 stars$13.95-0.9%$17.67+26.6%+16.8%$9.61B$29.05M-19.93860ELANElanco Animal Health2.8161 of 5 stars$18.63+0.5%$17.33-6.9%+28.7%$9.21B$4.44B21.669,000Positive NewsVRNAVerona Pharma PLC American Depositary Share2.2977 of 5 stars$106.37-0.1%$109.00+2.5%+257.2%$9.17B$42.28M-107.4430Positive NewsMRNAModerna4.4442 of 5 stars$23.88+1.6%$41.81+75.1%-65.0%$9.15B$3.24B-3.175,800RVMDRevolution Medicines4.2613 of 5 stars$46.20-0.8%$73.67+59.5%+5.7%$8.70B$11.58M-10.27250Insider TradeAnalyst Revision Related Companies and Tools Related Companies RDY Alternatives ASND Alternatives VTRS Alternatives QGEN Alternatives BBIO Alternatives ROIV Alternatives ELAN Alternatives VRNA Alternatives MRNA Alternatives RVMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLX) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredFree: The Crypto Summit That Could Change Your LifeWall Street’s Crypto Playbook—Revealed at This Free Event If you want to understand what's really happening...Crypto 101 Media | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Telix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TLX Stock Alerts